Essity Q1 margins rise on volume growth and acquisition gains By Investing.com

Essity reported improved Q1 operating performance, with EBITA margin excluding IAC rising 40 bps to 13.9% and gross margin expanding 70 bps to 33.5% on lower raw material costs. Reported net sales fell 5.1% to SEK 33.18 billion due to a 6.6 percentage point currency drag, but organic sales still grew 0.4% on 1.1% volume growth. The Edgewell feminine care acquisition added SEK 370 million in revenue, while the board also approved a new SEK 3 billion share buyback program after quarter-end.

Analysis

The key takeaway is not the modest headline growth; it is that mix, cost, and capital return are now working in the same direction. A sub-1x net leverage profile gives management room to keep buying back stock while digesting the new feminine-care assets, which means per-share earnings can compound faster than reported operating income if the integration holds. That combination typically rerates defensive consumer names when the market is still anchored to sluggish top-line optics.

The second-order winner is the North America personal-care shelf: the acquired brands deepen distribution leverage and improve bargaining power with retailers, which can offset weaker categories elsewhere. Competitors with less scale in feminine care and tissue will feel the pressure first through shelf-space competition and promotional intensity rather than immediate market-share losses; the more important margin risk is that category-level price competition in European tissue spills into adjacent paper and hygiene SKUs over the next 1-2 quarters.

The main near-term risk is FX, not demand. If the currency drag persists, reported numbers will continue to lag underlying execution and can keep the stock capped despite operational improvement; that makes this a better 3-6 month story than a 1-2 week catalyst trade. The buyback authorization is a clear signal that management sees the stock as cheap, but the market may need proof that the acquired business is accretive after integration costs before it assigns much value to that optionality.

Consensus is likely underestimating how much the repurchase program amplifies upside if margins stay stable and cash conversion normalizes. The contrarian concern is that investors are treating the acquisition as a clean growth bolt-on, when in reality the real payback depends on retailer execution and whether personal-care synergies offset tissue weakness. If margins in Consumer Tissue stabilize, the stock could grind higher; if they do not, the buyback simply masks a slower-quality earnings base.

Key Decisions for Investors

• Go long ESSITYb / EPC over 3-6 months on a relative-value basis: the setup favors a defensive compounder with buybacks and balance-sheet capacity versus a low-growth consumer peer set; target 8-12% upside if margin stability holds, with roughly 5-6% downside if FX and tissue pricing worsen.
• Add on weakness only if the stock sells off on currency noise, not on operating prints. Use any post-earnings fade of 3-5% to build a position ahead of the next two quarters, when acquisition accretion and buyback support should be more visible.
• Hedge the thesis with a short in a more tissue-exposed European consumer name or a basket short of higher-leverage packaging/paper peers; the risk is category pricing pressure spreading through the segment over the next 1-2 quarters.
• Sell downside protection only after the market has digested the buyback announcement: consider a 3-6 month put spread if implied vol stays elevated, because management's authorization provides a natural floor while reported FX volatility can keep premiums rich.
• If holding EPC, use this as a catalyst to trim only on a sharp rerating, not immediately; the best risk/reward is a staged exit into any move that prices the buyback plus acquisition synergies before they are fully reflected in consensus.